Epix Pharmaceuticals President Andrew Uprichard: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Uprichard discusses FDA’s recent encouraging response to Epix’s Vasovist appeal, the regulatory climate for imaging agents, and Epix’s conversion to therapeutics.
You may also be interested in...
FDA agrees to accept a “blinded re-read” of data on the vascular imaging agent as an NDA amendment after Epix appealed “approvable” requests for more studies.
Ambrisentan beats out Encysive's Thelin in race for FDA approval for treatment of pulmonary arterial hypertension.
A day after Epix announces plans to further appeal two FDA "approvable" letters for Vasovist, Uprichard discusses why he's taking his case to CDER Director Steve Galson.